A Massachusetts-based biotech company is stealing the show so far during Tuesday’s session after it announced that its investigational drug IMM-1-104 has received orphan...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Immuneering (NASDAQ:IMRX)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Immuneering
Grafico Azioni Immuneering (NASDAQ:IMRX)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Immuneering